司妥昔单抗与托珠单抗序贯治疗儿童特发性多中心型Castleman病1例

易萍, 张星星, 唐甜, 王英, 吴小川, 李杏芳

中国当代儿科杂志 ›› 2025, Vol. 27 ›› Issue (5) : 613-617.

PDF(1222 KB)
HTML
PDF(1222 KB)
HTML
中国当代儿科杂志 ›› 2025, Vol. 27 ›› Issue (5) : 613-617. DOI: 10.7499/j.issn.1008-8830.2412050
病例报告

司妥昔单抗与托珠单抗序贯治疗儿童特发性多中心型Castleman病1例

作者信息 +

Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report

Author information +
文章历史 +

摘要

患儿,女,11岁,因反复发热20 d,加重伴腹胀7 d入院。入院后患儿以反复发热、淋巴结及肝脾大、多浆膜腔积液及多器官功能障碍为突出表现,结合淋巴结病理结果及临床表现确诊为特发性多中心型Castleman病-TAFRO综合征,使用司妥昔单抗联合糖皮质激素治疗后改托珠单抗维持治疗,患儿病情得到控制。因此,当患儿一旦明确为特发性多中心型Castleman病-TAFRO综合征,应尽早使用司妥昔单抗以迅速缓解病情,后可尝试改用托珠单抗进行维持治疗。

Abstract

The patient, an 11-year-old girl, was admitted with recurrent fever for 20 days, worsening with abdominal distension for 7 days. Upon admission, she presented with recurrent fever, lymphadenopathy, hepatosplenomegaly, polyserositis, and multiple organ dysfunction. Lymph node pathology and clinical manifestations confirmed the diagnosis of idiopathic multicentric Castleman disease-TAFRO syndrome. Treatment with siltuximab combined with glucocorticoids was initiated, followed by maintenance therapy with tocilizumab. The patient is currently in complete clinical remission. Therefore, once a child is diagnosed with idiopathic multicentric Castleman disease -TAFRO syndrome, early use of siltuximab should be considered for rapid disease control, followed by tocilizumab for maintenance therapy.

关键词

Castleman病 / TAFRO综合征 / 司妥昔单抗 / 托珠单抗

Key words

Castleman disease / TAFRO syndrome / Siltuximab / Tocilizumab

引用本文

导出引用
易萍, 张星星, 唐甜, . 司妥昔单抗与托珠单抗序贯治疗儿童特发性多中心型Castleman病1例[J]. 中国当代儿科杂志. 2025, 27(5): 613-617 https://doi.org/10.7499/j.issn.1008-8830.2412050
Ping YI, Xing-Xing ZHANG, Tian TANG, et al. Sequential treatment with siltuximab and tocilizumab for childhood idiopathic multicentric Castleman disease: a case report[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(5): 613-617 https://doi.org/10.7499/j.issn.1008-8830.2412050

参考文献

1
中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国CASTLEMAN病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42(7): 529-534. PMCID: PMC8408489. DOI: 10.3760/cma.j.issn.0253-2727.2021.07.001 .
2
Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma[J]. Cancer, 1956, 9(4): 822-830. DOI: 10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4.
3
Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease[J]. Blood, 2017, 129(12): 1646-1657. PMCID: PMC5364342. DOI: 10.1182/blood-2016-10-746933 .
4
Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease[J]. Am J Hematol, 2016, 91(2): 220-226. DOI: 10.1002/ajh.24242 .
5
van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132(20): 2115-2124. PMCID: PMC6238190. DOI: 10.1182/blood-2018-07-862334 .
6
Yu L, Shi M, Cai Q, et al. A novel predictive model for idiopathic multicentric Castleman disease: the international Castleman disease consortium study[J]. Oncologist, 2020, 25(11): 963-973. PMCID: PMC7648372. DOI: 10.1634/theoncologist.2019-0986 .
7
Fajgenbaum DC, Langan RA, Japp AS, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease[J]. J Clin Invest, 2019, 129(10): 4451-4463. PMCID: PMC6763254. DOI: 10.1172/JCI126091 .
8
Sarosiek S, Shah R, Munshi NC. Review of siltuximab in the treatment of multicentric Castleman's disease[J]. Ther Adv Hematol, 2016, 7(6): 360-366. PMCID: PMC5089324. DOI: 10.1177/2040620716653745 .
9
张路, 李剑. 罕见病Castleman病的靶向治疗药物司妥昔单抗[J]. 中国医药导刊, 2022, 24(4): 299-304. DOI: 10.3969/j.issn.1009-0959.2022.04.001 .
10
刘海玲, 范磊, 李建勇. Castleman病的诊疗进展[J]. 中华血液学杂志, 2020, 41(8): 697-700. PMCID: PMC7525180. DOI: 10.3760/cma.j.issn.0253-2727.2020.08.017 .
11
van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2014, 15(9): 966-974. DOI: 10.1016/s1470-2045(14)70319-5 .
12
van Rhee F, Casper C, Voorhees PM, et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease[J]. Oncotarget, 2015, 6(30): 30408-30419. PMCID: PMC4745809 . DOI: 10.18632/oncotarget.4655 .
13
van Rhee F, Casper C, Voorhees PM, et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials[J]. Lancet Haematol, 2020, 7(3): e209-e217. DOI: 10.1016/s2352-3026(19)30257-1 .
14
Nishimoto N. Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan[J]. Clin Rev Allergy Immunol, 2005, 28(3): 221-230. DOI: 10.1385/CRIAI:28:3:221 .
15
陈航, 朱俪, 丁胜男, 等. 司妥昔单抗/托珠单抗治疗HHV-8阴性多中心型Castleman病的疗效及安全性单中心回顾性分析[J]. 中国医药指南, 2024, 22(31): 44-47. DOI: 10.15912/j.issn.1671-8194.2024.31.013 .

作者贡献声明

易萍负责数据收集、整理和分析、论文撰写;张星星负责文章的构思、设计与修改;唐甜、王英负责辅助数据收集、整理和分析;李杏芳及吴小川负责文章最终提供修改意见。


编委: 张辉

版权

版权所有 © 2023中国当代儿科杂志
PDF(1222 KB)
HTML

Accesses

Citation

Detail

段落导航
相关文章

/